BREAKING: Invivyd & leading researchers launch SPEAR Study Group to explore effects of mAb therapy on people suffering from Long COVID & post-vaccination syndrome. investors.adagiotx.com/news-releases/… #LongCOVID #LongCovidinvestors.adagiotx.com/news-release...in

Check out Marc Elia’s post about #mAbs: www.linkedin.com/posts/marc-e...

“Monoclonal antibodies: The next frontier in disease prevention.” | Marc Elia

“Monoclonal antibodies: The next frontier in disease prevention.” That headline says it all. And Aditya (Adi) Natu is right—and the frontier is here. The question now is whether we are able to cros...

linkedin.com

Summer can be full of risks for the immunocompromised, heatwaves and possible #COVID19 surges, too. Are you an organ transplant recipient? Before heading indoors, you should know there are more COVID-19 protection tools than just vaccines. Learn more: expandtheiroptions.com #summersurge

Are you at ASCO and need a quick, very entertaining break? Head on over to Out of Patients with Matthew Zachary, and listen to No One Told Me?! COVID and Cancer! @ascocancer.bsky.social @matthewzachary.bsky.social www.outofpatients.com/bonus-no-one...

Results from our landmark Phase 3 CANOPY trial are now published in Clinical Infectious Diseases. This marks meaningful progress in protecting vulnerable populations and shows our commitment to gold-standard science. We extend our sincere thanks to everyone involved. 🔗 Learn more: lnkd.in/eB-E3N2X

Earlier today, we announced a new pipeline discovery program focused on monoclonal antibody treatment for measles. Learn more: investors.invivyd.com/news-release... #measles

Invivyd's Chief Scientific Officer Robert Allen will be speaking at The World Vaccine Congress today as part of the Optimizing mAbs for Infectious Diseases workshop. Dr. Allen will also be participating on a keynote panel on 4/23 entitled "Prophylactic mAbs - coming of age." #WVCDC

Vaccines can only take us so far. Invivyd science breaks through biological limits to take us farther. #covid19 #monoclonalantibody #mAb #mAbs

#ICYMI Catch the recent episode of The Sick Times “Still Here” podcast where Invivyd’s Chairman Marc Elia speaks with co-host Miles Griffis about the role of monoclonal antibodies in the ongoing #covid endemic. thesicktimes.org/2025/02/14/i... #covid19 #LongCovid

#DidYouKnow? COVID-19 can cause vascular, systemic, thrombotic disease that damages every organ system. The best way to prevent long-term damage is to protect yourself from COVID-19. Don’t wait, visit www.expandtheiroptions.com for more information. #Covid19 #commonnotacold

We’re thrilled to team up with Coach Jim Harbaugh to raise awareness about COVID-19 options for those who are immunocompromised. There are options. If you or someone you care about is immunocompromised, click here now: bit.ly/3EqqpUT

April is Primary Immunodeficiency Month, a time to raise awareness about the more than 400 types of primary immunodeficiency disorders (PIDD). At Invivyd, we stand with the Primary Immunodeficiency community, many of whom may be vulnerable to the short-term and long-term impacts of COVID-19. 💙

We are thrilled to be at @escmid.bsky.social presenting a poster on the structure of VYD2311 & in vitro neutralisation against a panel of contemporary SARS-CoV-2 variants. #ESCMIDGlobal #mAbs #covid

💙🌿 Today marks National Living Donor Day and National Donate Life Blue and Green Day – days to honor those who selflessly donate life and give the gift of hope. At Invivyd, we are inspired by the courage and generosity of donors who make a lasting impact on the patients we serve.  #BlueGreenDay

We are thrilled to be at the 2025 Gulf Coast Hematology and Oncology Summit in Alabama! It is a privilege to meet colleagues who join us in their dedication to serve those living with cancer. #covid19 #cancer #oncology #hematology